Cytosorbents Corp (CTS) Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Cytosorbents Corporation is a medical device company focused on blood purification technologies, primarily through its CytoSorb device (approved in the EU) and the investigational DrugSorb-ATR (pending FDA approval in the US). The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $8.86 million | $8.73 million |
| Gross Profit | $6.13 million | $6.21 million |
| Gross Margin | 69.2% | 71.1% |
| Operating Loss | $(3.04) million | $(3.89) million |
| Net Loss | $(5.13) million | $(1.48) million |
| Net Loss Per Share | $(0.08) | $(0.02) |
| Cash & Equivalents (Unrestricted) | $4.81 million | $6.25 million |
| Total Debt (Principal) | $17.50 million | $17.50 million |
| Operating Cash Flow | $(1.16) million | $(3.47) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1.6% year-over-year, driven by double-digit growth in direct sales outside Germany. This was partially offset by a decline in the German market and delayed distributor orders in the Middle East due to geopolitical instability.
- Expense Reduction: Operating expenses decreased 9.1% to $9.17 million. Research and Development (R&D) expenses dropped 38.4% to $1.03 million following the completion of the STAR-T clinical trial. Selling, General, and Administrative (SG&A) expenses decreased 3.5% due to a 10% workforce reduction and lower stock-based compensation.
- Foreign Currency Impact: The company recorded a $1.23 million loss on foreign currency transactions in Q1 2026, compared to a $3.01 million gain in Q1 2025, primarily due to the weakening of the Euro against the US Dollar.
- Debt Structure: The company amended its Loan and Security Agreement with Avenue Capital Group in November 2025, receiving an additional $2.5 million (Tranche 2a) and extending the interest-only period to December 31, 2026.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. Unrestricted cash of $4.8 million may be insufficient to fund operations without additional financing.
- Regulatory Outlook: The FDA denied the original DrugSorb-ATR application in August 2025. The company plans to submit a new De Novo application in late 2026 or early 2027, incorporating additional mechanistic data and real-world evidence. Approval for the DOAC (Eliquis/Xarelto) indication is expected to follow the Brilinta approval.
- Cost Reduction: The company is executing a Strategic Workforce and Cost Reduction Plan, aiming to reach operating cash flow break-even in the second half of 2026.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting related to stock-based compensation accounting and financial statement consolidation. Remediation is ongoing.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.8 million unrestricted cash balance against the projected burn rate and the timeline for the next financing event.
- Debt Covenants: Confirm compliance with the Amended Loan and Security Agreement covenants, specifically the operating cash burn targets required to access Tranche 2b.
- Regulatory Timeline: Monitor the status of the new De Novo submission for DrugSorb-ATR and the specific data requirements requested by the FDA.
- Internal Control Remediation: Track progress on fixing the material weaknesses regarding RSU accounting and intercompany consolidation to ensure future financial statement reliability.
- Geopolitical Exposure: Assess the ongoing impact of Middle East instability on distributor sales and the Dubai subsidiary's performance.